3,5-二氨基甲苯 | 108-71-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二氨基甲苯
• 英文名称: 3,5-diaminotoluene
• 英文别名: 3.5-Diamino-toluol；1,3-diamino-5-methyl-benzene；5-methylbenzene-1,3-diamine
• CAS: 108-71-4
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: LVNDUJYMLJDECN-UHFFFAOYSA-N

物化性质

• 熔点：
  98.1°C
• 沸点：
  217.6°C (rough estimate)
• 密度：
  1.0343 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）
• 蒸汽压力：
  0.00159 mm Hg at 25 °C(est).

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

ADMET

毒理性

• 副作用

职业性肝毒素 - 第二性肝毒素：职业环境中毒性效应的潜在性是基于人类摄入或动物实验的中毒案例。 高铁血红蛋白血症 - 血液中高铁血红蛋白含量增加；该化合物被归类为第二毒性效应 生殖毒素 - 对生殖系统有毒的化学物质，包括对后代缺陷以及男性或女性生殖功能的损害。生殖毒性包括发育效应。参见生殖毒性风险评估指南。 皮肤致敏剂 - 能够诱导皮肤过敏反应的制剂。

Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation. Methemoglobinemia - The presence of increased methemoglobin in the blood; the compound is classified as secondary toxic effect Reproductive Toxin - A chemical that is toxic to the reproductive system, including defects in the progeny and injury to male or female reproductive function. Reproductive toxicity includes developmental effects. See Guidelines for Reproductive Toxicity Risk Assessment. Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 人类毒性摘录

环境和医学调查已经进行……以评估工人接触二硝基甲苯和甲苯二胺的情况。在最初的调查中，二硝基甲苯和甲苯二胺的浓度范围为0.013-0.42毫克/立方米，在随后的调查中，浓度范围为未检出至0.10毫克/立方米。医学发现包括接触工人的精子数量显著减少。接触工人的妻子流产率略有增加，但无法确定与接触有明确的关联。

Environmental and medical surveys were conducted ... to evaluate dinitrotoluene and toluenediamine exposures /of/ workers. ... Dinitrotoluene and toluenediamine concentrations ranged from 0.013-0.42 mg/cu m during the initial survey and from undetectable to 0.10 mg/cu m during the follow-up survey. ... Medical findings included a significant reduction in sperm count among exposed workers. A slight excess of miscarriages among the wives of exposed workers was found, but could not be conclusively related to the exposures. ...

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

甲苯二胺用作睫毛染料在一个实例中据报道引起了角膜结膜炎和睑缘炎，伴有角膜混浊，这些症状在几周内逐渐清除。/甲苯二胺/

... Toluenediamine used as a dye on the eyelashes is reported in one instance to have caused keratoconjunctivitis and blepharitis with opacities of the cornea which gradually cleared in the course of several weeks. /Toluenediamine/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

某些二胺（例如，甲苯二胺和二氨基二苯甲烷）在实验动物中具有强烈的肝毒性作用... /甲苯二胺/

Certain diamines (eg, toluenediamine and diaminodiphenylmethane) have potent hepatotoxic effect in experimental animals ... . /Toluenediamines/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

根据对家兔眼睛的测试，甲苯二胺似乎不是原发性刺激物。测试中，将每种异构体的0.02 M溶液在pH 6.5条件下，滴在家兔眼睛上，持续十分钟，之前已机械去除角膜上皮以允许渗透。眼睛在两到四天内愈合并恢复正常，没有化学性损伤的迹象。/甲苯二胺/

The toluenediamines appear not to be primary irritants, according to tests on rabbit eyes in which 0.02 M solutions of each of the isomers all at pH 6.5 were tested by dropping on rabbit eyes for ten minutes after mechanical removal of the corneal epithelium to permit penetration. The eyes healed and returned to normal within two to four days without evidence of chemical injury. /Toluenediamines/

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 海关编码：
  2921519090
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  3,5-二氨基甲苯 在 N-甲基吗啉 、 吡啶 作用下， 以 乙醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  New analogues of AHMA as potential antitumor agents: synthesis and biological activity

  摘要：

  A series of new analogues of 3-(9-acridinylamino)-5-hydroxymethylaniline (AHMA, 1) and AHMA-ethylcarbamate (2) were synthesized by introducing an O-alkylcarboxylic acid esters to the CH2OH function, displacing the CH2OH function with a dimethylaminocarboxamido group or with a methyl function introduced at the meta-, para- or ortho-position to the NH2 group to form 5-(9-acridinylamino)-m-toluidines (AMTs), 5-(9-acridinylamino)-p-toluidines (APTs) or 5-(9-acridinylamino)-o-toluidines (AOTs), respectively. The inhibitions of a variety of human tumor cell growth, interactions with DNA as well as inhibitory effect against topoisomerase 11 (Topo 11) of these new agents were studied. Among AMT, APT and AOT derivatives with dimethylaminoethylcarboxamido and Me at C4 and C5 of acridine moiety (i.e., 21c, 23c and 26c) were more cytotoxic than AHMA (1) and AHMA-ethylcarbamate (2), depending upon the tumor cell line tested. Detailed structure-activity relationships of the new analogues were studied. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.09.001
• 作为产物：
  描述：

  4-甲基乙酰苯胺 在 盐酸 、 tin 、 硫酸 、 硝酸 作用下， 以 水 为溶剂， 反应 1.0h， 生成 3,5-二氨基甲苯
  参考文献：
  名称：

  溴甲基取代的cr啶的DNA相互作用

  摘要：

  合成了具有双功能取代基的一系列of啶，具有DNA烷基化和嵌入的双重特性。以前有报道称4,5-双（溴甲基）ac啶（1）与DNA交联和嵌入。在这项研究中，1,8-二（溴甲基）吖啶（2）和2,7-双（溴甲基）吖啶（3），单官能的2-（溴甲基）-7-甲基吖啶（4）和2,7- dimethylacridine（合成了5），并研究了它们的交联和插入活性以评估溴甲基a啶与DNA的反应性。三种双（溴甲基）ac啶之间的链间交联活性相似。cr啶对小牛胸腺DNA的插入活性如下：3  >  4  >  2  =  1  >>>  5。使用Ames分析评估细胞内DNA交联和DNA嵌入活性。图4在鼠伤寒沙门氏菌TA100和TA98中是诱变的，表明溴甲基烷基化的DNA碱基。在鼠伤寒沙门氏菌TA92和TA94中，所有三个双（溴甲基）ac啶都是诱变的，它们可以检测细胞内交联DNA损伤，而在这些菌株中，没有五个是诱变的。结果

  DOI：

  10.1007/s00044-017-2030-7

文献信息

• [EN] PROCESS FOR PREPARING ISOCYANATE COMPOUND<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ ISOCYANATE
  申请人：BASF SE

  公开号：WO2016177761A1

  公开（公告）日：2016-11-10

  The present invention relates to a process for the preparation of an isocyanate compound comprising the steps of: a) Reacting an amine compound A having at least one primary amino group with CO2 and an organotin compound S having at least one radical OR3 attached to the tin atom of the organotin compound, wherein R3 is a C-bound organic radical having from 1 to 30 carbon atoms, wherein 1, 2 or 3 carbon atoms may be replaced by oxygen or nitrogen, to convert at least one of the primary amino groups in the amine compound A into a carbamate group, thereby obtaining a carbamate compound C; b) cleavage of the carbamate groups in the carbamate compound C obtained in step a) to form the isocyanate compound and an alcohol R3OH, without separation of the tin compound formed in step a); c) obtaining the isocyanate compound from the reaction mixture of step b).

  本发明涉及一种用于制备异氰酸酯化合物的方法，包括以下步骤：a）使至少含有一个伯氨基的胺化合物A与CO2和至少含有一个连接到有机锡化合物锡原子的自由基OR3的有机锡化合物S反应，其中R3是一个具有1至30个碳原子的C-连接有机基团，其中1、2或3个碳原子可以被氧或氮替换，以将胺化合物A中的至少一个伯氨基转化为碳酸酯基团，从而获得碳酸酯化合物C；b）在步骤a）中获得的碳酸酯化合物C中的碳酸酯基团裂解，形成异氰酸酯化合物和醇R3OH，不分离步骤a）中形成的锡化合物；c）从步骤b）的反应混合物中获得异氰酸酯化合物。
• PHOTOREACTIVE COMPOUNDS
  申请人：Lincker Frederic

  公开号：US20140192305A1

  公开（公告）日：2014-07-10

  The present invention relates to photoreactive compounds that are particularly useful in materials for the alignment of liquid crystals.

  本发明涉及光反应性化合物，特别适用于液晶对准材料的制作。
• METHOD FOR PRODUCING ISOCYANATES IN THE GAS PHASE
  申请人：Covestro Deutschland AG

  公开号：US20170305842A1

  公开（公告）日：2017-10-26

  The invention relates to a method for producing isocyanates by reacting the corresponding primary amines with phosgene in the gas phase, wherein the phosgene is injected into the gaseous amine flow in the interior of the flow tube via an outer ring channel and through several radial channels in an angle of ≦90° relative to the flow direction of the gaseous amine flow, wherein a static mixer of the KENICS type is provided coaxially in the interior of the flow tube.

  该发明涉及一种通过在气相中将相应的一次胺与光气反应来生产异氰酸酯的方法，其中光气通过外环通道注入到气态胺流中，在流管的内部，并通过几个与气态胺流的流动方向成≦90°角度的径向通道注入，其中在流管的内部同轴设置了KENICS类型的静态混合器。
• 5-(9-ACRIDINYLAMINO)-TOLUIDINE COMPOUNDS
  申请人：——

  公开号：US20040198765A1

  公开（公告）日：2004-10-07

  This invention relates to 9-anilinoacridine compounds, and more particularly to their synthesis and their use in pharmaceutical compositions for treating diseases.

  这项发明涉及9-苯胺基吖啶化合物，更具体地涉及它们的合成以及它们在制备治疗疾病的药物组合物中的应用。
• 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of
  申请人：Syntex (U.S.A) Inc.

  公开号：US05952362A1

  公开（公告）日：1999-09-14

  The present invention concerns novel compounds represented by the Formula: ##STR1## wherein: A is R.sup.1.sub.q (R.sup.3 R.sup.60 N).sub.m (Z)(NR.sup.2).sub.n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C.dbd.O or SO.sub.2 ; n is 1 with the proviso that, when Z is C.dbd.O, m is 1; X is --NH--, --CH.sub.2 --, or --OCH.sub.2 --; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R.sup.1 is H, lower alkyl, or phenyl, with the proviso that, when R.sup.1 is H, m is 1; R.sup.2, R.sup.3, R.sup.60 are each independently H, lower alkyl, or phenyl; R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are each independently hydrogen, lower alkyl, --CF.sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R.sup.2 and R.sup.7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5- or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or --CN, with the proviso that, when R.sup.7 is hydroxyl or lower alkylsulfonamido, then X is not --NH-- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R.sup.1 SO.sub.2 NR.sup.2 --), (R.sup.3 R.sup.60 NSO.sub.2 NR.sup.2 --), or (R.sup.3 R.sup.60 NCONR.sup.2 --). The invention also includes the use of the above compounds, and compositions containing them, as alpha.sub.1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.

  本发明涉及由以下式表示的新化合物：##STR1## 其中：A为R.sup.1_sub_q(R.sup.3 R.sup.60 N).sub.m(Z)(NR.sup.2).sub.n；m和q各为0或1，但条件是当q为1时，m为0，当q为0时，m为1；Z为C.dbd.O或SO.sub.2；n为1，但条件是当Z为C.dbd.O时，m为1；X为--NH--，--CH.sub.2--或--OCH.sub.2--；Y为2-咪唑啉，2-噁唑啉，2-硫唑啉或4-咪唑醇；R.sup.1为H，低碳烷基或苯基，但条件是当R.sup.1为H时，m为1；R.sup.2，R.sup.3，R.sup.60各自独立地为H，低碳烷基或苯基；R.sup.4，R.sup.5，R.sup.6和R.sup.7各自独立地为氢，低碳烷基，--CF.sub.3，低烷氧基，卤素，苯基，低烯基，羟基，低烷基磺酰胺基或低环烷基，其中R.sup.2和R.sup.7可选择地结合在一起形成未取代或可选择取代的5-或6-成员环的2至3个原子的烯烃或烷基，环上的可选择取代基为卤素，低碳烷基或--CN，但条件是当R.sup.7为羟基或低烷基磺酰胺基时，当Y为2-咪唑啉时，X不是--NH--。这些化合物包括上述的药用盐。在上述的式子中，A可以是(R.sup.1 SO.sub.2 NR.sup.2--)，(R.sup.3 R.sup.60 NSO.sub.2 NR.sup.2--)或(R.sup.3 R.sup.60 NCONR.sup.2--)。该发明还包括上述化合物的使用，以及含有它们的组合物，作为α.sub.1A/1L激动剂用于治疗各种疾病状态，如尿失禁、鼻塞、勃起异常、抑郁症、焦虑症、痴呆、老年痴呆症、阿尔茨海默氏病、注意力和认知缺陷、以及如肥胖症、暴食症和厌食症等的进食障碍。